Oncotype DX Breast Cancer Testing
A Contract Award Notice
by EAST SUSSEX HEALTHCARE NHS TRUST
- Source
- Contracts Finder
- Type
- Contract (Services)
- Duration
- 1 year
- Value
- £136K-£273K
- Sector
- HEALTH
- Published
- 03 Mar 2026
- Delivery
- 01 Apr 2026 to 31 Mar 2027
- Deadline
- 04 Feb 2026 12:00
Related Terms
Location
Geochart for 1 buyers and 1 suppliers
1 buyer
- East Sussex Healthcare NHS Trust Saint Leonards on Sea
1 supplier
- Exact Sciences London
Description
Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient.
Award Detail
| 1 | Exact Sciences (London)
|
CPV Codes
- 85111800 - Pathology services
Other Information
This is a call off contract from framework 2023/S 000-028831 based on previous contracts usage.
Reference
- CF-3414000D0O000000rwimUAA
- CF be83749f-55db-4eb4-b59b-40aa06ac75c4